Category Archives: Molecular Medicine

NEW YORK, Dec. 17, 2019 /PRNewswire/ -- Hoth Therapeutics,Inc. (NASDAQ: HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announcedthe addition of Dr.William Weglicki, M.D. to the Company's Scientific Advisory Board. While serving on the Board, Dr, Weglicki will oversee Hoth's Aprepitant Program under its Scientific Research Agreement with the George Washington University ("GW").

Mr.Robb Knie, CEO of Hoth Therapeutics, commented, "I am pleased to welcome Dr. Weglicki to our Scientific Advisory Board.Dr. Weglicki will be instrumental towards the advancement of our Aprepitant program.Hoth is fortunate to have such well-respected leaders providing their invaluable expertise and insight to each of our significant research and development initiatives."

Dr. Weglicki isProfessor of Biochemistry and Molecular Medicine at the George Washington University School of Medicine.Dr Weglicki is a recipient of the Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery, The International Academy of Cardiovascular Sciences. After completing a medical residency at Georgetown University Hospital in 1964 he completed a Cardiology fellowship in 1966 at Duke University where he trained in clinical cardiac catheterization and pharmacology basic research. He was then appointed as a research associate at NIH's NICHHD and the McCollum Pratt Institute of the Johns Hopkins University where he studied the cardiac pathobiology of alpha tocopherol deficiency. In 1968 He joined Harvard's Peter Bent Brigham Hospital Department of Medicine's Cardiovascular Research unit, androse from Instructor to Associate Professor in 1975. There he concentrated his research on the role of phospholipases of the heart in the ischemic perturbation of cardiac membrane phospholipids and organelles, which led to several RO1 NIH grant awards. With his research team he moved to the Medical College of Virginia/VCU in 1975 as chairman of the Department of Biophysics and served as a professor of Medicine (Cardiology); there he was active in teaching medical and mentoring graduate students, while publishing a series of manuscripts on cardiac lysosomal activity in myocardial ischemia and the distribution of phospholipases in cardiac mitochondria and sarcolemmal membranes, and overseeing a new NHLBI Training Grant on molecular mechanisms of cardiovascular injury. At the Oklahoma Medical Research Foundation he led their Cardiovascular Research Program. He joined the George Washington University Department of Medicine in 1985 and formed the Division of Experimental Medicine; in 1987 this core group of investigators was awarded a Program Project grant on Molecular Mechanisms of Cardiovascular Injury from the National Heart, Lung, and Blood Institute. This research included identifying free-radical peroxidative injury during myocardial ischemia and the protective antioxidant properties of cardiac beta blocking drugs such as propranolol and carvedilol. At present he is a Professor of Biochemistry and Molecular Medicine and Medicine (Cardiology). He has been a principal investigator of NIH grants for more than thirty years. His ongoing research focuses on preventing neurogenic inflammation and hyomagnesemia effects associated with some anticancer drugs.

About Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. isa clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visitwww.hoththerapeutics.com.

Forward Looking StatementsThis press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period endingDecember 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

ContactsInvestor Relations Contact:Phone: (646) 756-2997Email:investorrelations@hoththerapeutics.comwww.hoththerapeutics.com

KCSA Strategic CommunicationsValter Pinto / Daniela Guerrero(212) 896-1254 / (212) 682-6300Hoth@kcsa.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-the-appointment-of-dr-william-weglicki-md-to-scientific-advisory-board-300976186.html

SOURCE Hoth Therapeutics, Inc.

See more here:
Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board - P&T Community

- Presentation Demonstrates Advantages of iBios Recently Launched FastGlycaneering Development Service -

NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) presented results of the application of its new FastGlycaneering Development Serviceto enhance potency of recombinant proteins at last weeks Antibody Engineering & Therapeutics conference in San Diego, CA. Specifically, the presented data demonstrated the ability to deploy iBios glycan engineering technologies and plant-based manufacturing platform to rapidly develop and produce biobetters, such as the biobetter rituximab (iBio Rituximab) product candidate currently being developed in collaboration with CC-Pharming Ltd.

Dr. Sylvain Marcel, iBios Vice President of Protein Expression Sciences, highlighted laboratory results showing how iBios FastGlycaneering Technology enables greater N-linked glycosylation customization and control. In the case of iBio Rituximab, antibody dependent cellular cytotoxicity was increased 30-fold; potency, as measured by half maximal effective concentration, was substantially improved versus the control antibody; and iBios glycan engineering methods were shown to be capable of producing antibodies with more homogeneous and fully human glycosylation patterns.

This study demonstrated that our complementary glycan engineering technology can improve the activity of therapeutic antibodies, which is instrumental in the development of antibodies with higher potency, stated Dr. Marcel. These data represent a very positive development within our collaboration with CC-Pharming and, in addition, highlight iBios ability to produce antibodies with more homogeneous and humanized glycosylation patterns, which can help our other clients and partners achieve their target product profiles.

In addition to joint work on a biobetter rituximab, iBio and CC-Pharming are undertaking joint product assessments in other categories that, in some cases, may reach the commercial stage faster than is possible with therapeutic antibodies. The companies expect to use iBios FastGlycaneering Technology for any glycoproteins selected from the initial candidate pool for advancement to commercial development.

In August 2019, iBio granted to CC-Pharming an exclusive, royalty-bearing commercial license to iBio Rituximab product candidates for the territory of China, as well as a research license to iBios FastPharming System and know-how for the evaluation of multiple product opportunities.

About CC-Pharming Ltd.

CC-Pharming is located in Zhongguancun Biomedical Engineering Transformation Center, Shunyi District, Beijing, China. The company is specialized in plant molecular medicine technology research and product development using proprietary tobacco and lettuce transient expression platforms, focusing on the use of plant bioreactors for the development of animal-free, safe, high-value recombinant protein and peptide product for industrial and clinical applications. The Company develops innovative indoor vertical farming system for efficient plant-based expression systems, and offers therapeutic biomedicine, life science research, cosmetics, and CRO/CMO services to clients in China. Further information is available at http://www.cc-pharming.com.

About iBio

iBio, Inc., is a global leader in plant-based biologics manufacturing. Its FastPharming System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Companys subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas. iBio CDMO also enables innovators to use the FastPharming System for insourced manufacturing via its Factory Solutions design-and-build services. iBios FastGlycaneering Development Service includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing its own proprietary products which include its lead asset, IBIO-100, for the treatment of fibrotic diseases. For more information, visit http://www.ibioinc.com.

Story continues

FORWARD-LOOKING STATEMENTSSTATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen KilmerInvestor Relations(646) 274-3580 skilmer@ibioinc.com

Visit link:
iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming - Yahoo Finance

Atomic-level studies of the architecture of tiny sodium channel proteins, critical to generating electrical signals that start off each beat of the heart, are imparting striking details about their function, malfunctions, disruption by many disease mutations, and response to medication.

This structural information could become the basis for developing better diagnostics and drugs for life-threatening heart rhythm problems, according to the researchers from the University of Washington School of Medicine working in this area.

Their latest findings appear Dec. 19 in Cell in the paper, Structure of the Cardiac Sodium Channel. The senior authors are William Catterall and Ning Zheng, both UW School of Medicine professors of pharmacology. The first authors are Daohau Jiang and Hui Shi, UW postdoctoral fellows in pharmacology.

The cardiac sodium channel not only initiates the heartbeat, mutations in it also cause deadly arrhythmias, and antiarrhythmic drugs act directly on it to control cardiac rhythms, explained Catterall.

The heart is both a plumbing and electrical marvel. For each heartbeat, electrical waves travel across a healthy heart in a pattern that controls its filling and pumping in a tightly coordinated manner. The rate at which the impulse is propagated through the heart tissue relies on actions taking place at the molecular level in tiny protein pores present in cardiac cell membranes.

Sodium ions a type of charged particles -- pass through these protein passageways in the membrane boundary between the outside and inside of the cell.

Pufferfish harbor a toxin that acts on nerve and muscle, but not heart, sodium channels.

The activation and quick inactivation of these voltage-gated sodium channels are part of a series of electrical and physiological events that maintain a steady heartbeat.

Sodium channels operate in concert with calcium channels and potassium channels to drive the heartbeat at a consistent frequency for our entire lives, Zheng noted.

When sodium channels dont work properly, the heart can be in trouble, even to the point of having dangerously fast and uncoordinated contractions that are life-threatening, the researchers explained. Specifically, the NaV (Latin abbreviation for sodium, V for voltage) 1.5 channel has such an indispensable role that certain mutations in those channels can be fatal, because other sodium channels in the heart cannot compensate for their loss. These mutations can cause dangerous arrhythmias in adults and even sudden death in children and young athletes.

Fortunately, many heart rhythm disturbances can be treated with drugs that block cardiac sodium channels. For example, as UW Medicine physician Michael Lenaeus, a UW assistant professor of medicine, Division of General Internal Medicine, and a co-author of the study, noted, atrial fibrillation, or A-fib, is increasingly prevalent among older Americans. This condition can often be treated effectively with the drug flecainide. In their recent study, the researchers sought to learn, among other things, how drugs like flecainide act within the predominant form of sodium channels found in cardiac cells.

To obtain a high-resolution, 3-D map of the channels, the scientists used advanced cryo-electron microscopy at the new Beckman Center for Cryo-EM at the UW. They wanted to explore important structural features of these sodium channels and relate their configuration to their actions in normal physiological function, dysfunction, disease mutations, toxin sensitivity and the pharmacology of antiarrhythmic drugs.

According to the scientists, their experiments provide a blueprint for understanding many various aspects of cardiac sodium channels.

Among the key findings from this work were:

An electrocardiogram record of the electrical activitiry of the heartbeat

In their conclusion, the researchers noted that, overall, the detailed, high-resolution structures they were able to obtain for the cardiac NaV1.5 channel allowed them to elucidate the molecular basis for several

of its specific, distinctive, vital functions and to provide key chemical information for design and development of safer and more effective antiarrhythmic medications.

Our high-resolution cryoEM structure of this iconic sodium channel gives new structure/function insights, reveals the molecular mechanisms of many inherited arrhythmias, and elucidates the exact binding site and blocking mode of the antiarrhythmic drug flecainide, which is used to treat atrial fibrillation, an increasingly prevalent problem in our aging population, Catterall said in summarizing the results.

The research was funded by the National Institutes of Health (R01HL112808) and the Howard Hughes Medical Institute.

More:
An atomic view of the trigger for the heartbeat - UW Medicine Newsroom

By Michelle Morgante, UC Merced

Proteins are miniscule machines inside the body, about 10,000 times smaller than the thickness of human hair. They control all the processes of life like how cells communicate to each other, how the immune system combats infection, how muscles contract, and how oxygen is picked up in the lungs and delivered to those very same muscles.

Proteins can do all of this because they change shape, assemble and interact with other biomolecules in response to specific cues. This general property makes proteins extremely attractive targets for a variety of applications in medicine, environment, food industry and energy. But it also has proven very difficult to harness. Now, bioengineering Professor Victor Muoz has made a key discovery that could allow scientists to engineer adaptive proteins and convert them into powerful technological applications, including smart medicines.

In a paper published Dec. 13 in Nature Communications, Muoz and a team of researchers describe how they were able to engineer proteins to form assemblies, dissociate and change shape in response to signals. The discovery could allow scientists to, for example, use proteins to deliver drugs in a way that is less toxic and more targeted than current practices.

Proteins in their natural state are easily passed through the kidney, meaning they are not in the blood long enough to act as an effective medicine.

But when a protein makes an assembly, Muoz said. It forms structures that are larger and sturdier and dont get secreted out of the kidney. They stay in the blood for a longer time.

Muoz, who is director of UC Merceds Center for Cellular and Bio-Molecular Machines (CCBM-CREST), said research for this project began a decade ago and has involved collaboration from several groups around the world. The work to figure out how to engineer proteins to act as nanomachines has been challenging and tortuous.

They do all these complicated things and are so small. That means their design principles and organization are incredibly sophisticated, he said. People have been able to design proteins that will form particular assemblies of many different shapes, but they have not been able to make them adaptive so they switch their shape and properties in response to stimuli.

"This opens the gate for developing drugs that are based on proteins in a way they could be delivered as inactive assemblies that remain in the blood as needed to then be activated on cue at a given time or in a specific location in the body."

director, Center for Cellular and Bio-Molecular Machines

The discovery may lead to important applications in biosensor research, medicine, diagnostics, vaccines, bioremediation anything you could imagine, Muoz said.

In medical applications, for example, proteins engineered this way could become a new technology for the smart delivery of specific drugs.

This would have enormous advantages over conventional drugs, which are much less specific, more toxic and can cause a range of harmful side-effects. It could also help store an inactive version of the protein in blood for a relatively long time, eliminating the short lifespan curse of current protein pharmaceuticals.

This opens the gate for developing drugs that are based on proteins in a way they could be delivered as inactive assemblies that remain in the blood as needed to then be activated on cue at a given time or in a specific location in the body, Muoz said.

The next step, Muoz said, will be to try the process in other systems and see whether it can be generalized. This was a proof of concept. Next, wed like to target systems that have more interesting applications to exploit the possibility of making this into a real technology thats useful.

View post:
Engineered Protein Assemblies that Respond to Cues Open Path for Smart, Protein-Based Medicines | Newsroom - UC Merced University News

By TNH Staff December 22, 2019

Dr. Steven Kalkanis, CEO of the Henry Ford Medical Group. (Photo: Courtesy of the Henry Ford Medical Group)

DETROIT, MI On December 19, the nationally-recognized Henry Ford Health System announced the selection of world-renowned neurosurgeon Dr. Steven Kalkanis as Chief Executive Officer of the Henry Ford Medical Group.

The text of the news release follows:

Following an extensive national search, Henry Ford Health System has selected its own Dr. Steven N. Kalkanis, to be the Chief Executive Officer of the Henry Ford Medical Group (HFMG), effective Jan. 1, 2020. He succeeds Dr. William A. Conway who is stepping down after more than four decades with the health system.

Dr. Kalkanis will provide strategic leadership and direction over the 1,900-member group of physicians and researchers, responsible for all aspects of clinical performance across 40 specialties. Additionally, Dr. Kalkanis will also serve as Henry Fords Senior Vice President and Chief Academic Officer, working to advance the health systems academic mission, including the development and advancement of all research and medical education programs.

We are proud to welcome Dr. Steven Kalkanis to this expanded role, said Wright L. Lassiter, III, President and CEO, Henry Ford Health System. Not only is Steve an accomplished and recognized neurosurgeon, he is a transformational leader who can build on the strong history and tradition of the Henry Ford Medical Group. We are excited to partner with him to drive the innovative approaches for which this medical group has long been known.

Dr. Kalkanis will also work collaboratively with health system clinical and operational leaders, as well as national and community partners to provide exceptional patient care and advance the health systems population health and accountable care strategies. Dr. Adnan Munkarah, Henry Ford Health Systems Executive Vice President and Chief Clinical Officer, said Dr. Kalkanis brings the kind of dynamic leadership that will help Henry Ford maintain its leading role in this area. Creating meaningful solutions for our patients and members that provide the most advanced, innovative, highest quality and safest care at the lowest possible cost cannot be done without strong, committed leadership and trusted partners. Steve is a truly collaborative leader who always acts in the best interests of his patients and their families, as well as his colleagues. We are confident that he can build critical partnerships both inside and outside our organization as we work to achieve lasting health and wellness in the communities we serve.

Dr. Kalkanis joined Henry Ford in 2004 and is currently the Chair of the health systems Department of Neurosurgery, ranked among the nations best by U.S. News and World Report. He is also the Medical Director of the Henry Ford Cancer Institute, leading the expansion of cancer care services across the system, including the spearheading of a comprehensive precision medicine and molecular tumor board program for all cancer types, and the development of the health systems new destination cancer facility, expected to open in 2020.

I am honored to follow in the footsteps of such a storied and respected leader of the Henry Ford Medical Group, said Dr. Kalkanis. To have the opportunity to be part of a compassionate and diverse culture that is relentless in its pursuit of clinical innovation, pioneering research and next generation medical education has been a privilege. In this new capacity, I am more committed than ever to stewarding transformational healthcare through a combination of precision medicine and digital advancements, distinctly personalized care, value-based solutions and a dedication to addressing the real challenges in our communities.

An internationally recognized brain tumor expert, Dr. Kalkanis currently serves as President of the Congress of Neurological Surgeons (CNS), the largest association of its kind. In 2018, he was also named a Director of the American Board of Neurological Surgery, the official accrediting and credentialing body for all neurosurgeons practicing in the U.S. Actively involved in clinical trials and research, he leads a translational research laboratory investigating the molecular genetic differences between short and long term brain tumor survivors with the goal of refining future personalized medicine treatment protocols. He has also served as a visiting professor and guest lecturer for more than 100 national and international audiences and has authored more than 150 peer-reviewed publications.

A metro Detroit native, Dr. Kalkanis completed his neurosurgical training at Massachusetts General Hospital in Boston. He is a graduate of both Harvard University and Harvard Medical School.

More information about the HFMG is available online: https://www.henryford.com/about/hfmg.

See original here:
Dr. Steven Kalkanis Selected as CEO of Henry Ford Medical Group - The National Herald

'TIS the season for too much to drink, not enough sleep and increased anxiety.

So it's not surprising blokes are likely to struggle getting - and keeping- an erection over the festive period.

7

Unfortunately, impotence rates have doubled in the last 25 years, according to a new study by Kings College, London - and young men are increasingly affected.

A third blamed tiredness, a third anxiety and a third drinking too much - all factors which increase at this time of year.

But these six surprising Christmas gift ideas might just help perk up your lovers performance.

It might not sound like a sexy stocking filler, but scientists say a tongue-scraper could work wonders for your mans performance.

Thats because using the metal device to remove surface debris from the tongue allows good oral bacteria to flourish, producing chemicals called nitrites, which build up in the saliva.

7

When your lover swallows, the nitrites mix with the acid of his stomach and turn it into nitric oxide, giving a boost to the blood-flow to his manhood.

Dr Nathan Bryan, a specialist in molecular medicine from Baylor College of Medicine, Texas, says: "With enough nitric oxide you can dilate blood vessels, increase blood flow and improve sexual function."

While your man is busy in the bathroom scraping his tongue, get him flossing too.

Several studies have found that men with gum disease are more likely to have problems getting and keeping erections.

Chronic inflammation caused by gum disease can damage the lining of the blood vessels in his penis, reducing healthy blood flow into the organ.

In fact, if a man has serious gum disease, hes more than twice as likely to have problems between the sheets, according to a study of more than 200,000 men aged 20 to 80.

7

Brew up some coffee in the morning, if youd like to see a stronger performance from your man in the bedroom.

Just two or three cups a day could really perk him up, according to researchers at the University of Texas.

After studying the coffee-drinking of 4000 men, they found that those who enjoyed a couple of coffees were 42 per cent less likely to have erectile dysfunction.

Its thought that ingredients in coffee relax the arteries in the penis and allow more blood to flow into it.

7

Many men believe that eating meat is a sign of virility.

But recent research suggests its actually vegans who are likely to perform better in the bedroom.

US urologist Dr Aaron Spitz decided to conduct an experiment. One night, he gave men burritos containing beef, chicken or pork. The next, the burritos contained plant-based meat substitutes.

While they slept, the men wore special devices to monitor penile length and girth.

In the mornings, it was found that that men who ate the plant-based burritos had erections which lasted three to four times longer.

Why? Possibly because diets high in animal fats and rich in cholesterol can clog up the arteries, restricting blood flow to the penis. But plant-based foods boost nitric oxide, increasing blood flow.

Dr Spitz said: "What the scientific studies are showing is that the more meat men eat, the more quickly they lose their manly manhood."

Consultant urological surgeon Mr Vivek Wadhwa, who is based at Birminghams Spire Parkway Hospital, says the strength of your mans erection can be a red flag for future heart problems.

"The small arteries in the penis tend to fur up (with fatty deposits) a good 10 to 15 years earlier than the bigger arteries to the heart and brain.

So it can help for a man to reduce his intake of animal protein and increase plant fibre and antioxidants in the diet when he gets this early warning sign.

7

If your man is a lycra cycling warrior, it might be doing wonders for his physique but not much for his endurance in the bedroom.

Very active male cyclists have twice the rate of erectile dysfunction than non-cyclists, according to a study of 6,751 men by the University of Hamburg.

Certain mens bikes which make the rider lean forward and hold on to dropped handlebars - can press on the artery into the penis - as well as the blood vessels and nerves between the scrotum and anus.

This can cause pain, numbness and damage.

However, the effect can be lessened with padded cycling shorts which reduce pressure.

Or another option could be to buy him a new saddle with grooves in the middle.

A study in the British Journal of Urology International found that this type of seat is less numbing and less likely to cause erection problems.

Mr Wadhwa told The Sun: "I also tell patients that if they change their saddle to something softer theres not so much pressure on the perineum - the area between the scrotum and anus."

7

Baste your Christmas dinner roast potatoes in olive oil, not chicken fat - it could be better than Viagra at reducing impotence as it boosts testosterone.

Researchers from the University of Athens found that eating just nine tablespoons of olive oil a week does the trick.

Study leader, Dr Christina Chrysohoou, said diet and exercise were key to improving a mens sexual performance.

Men who follow a Mediterranean diet particularly consuming lots of olive oil see their risk of impotence reduced by up to 40 per cent in older age."

7

YULE HOUSE Pregnant mum-of-21 Sue Radford gives kids' rooms a Christmas makeover

NOW HEIR THIS Kate & William to make big announcement over Christmas, says royal expert

HAPPY MEAL-TIMEs Dad shares genius tip for giving daughter a McDonalds Happy Meal at home

RING THE CHANGES Can YOU tell the difference between a 21,400 ring and its 100 dupe?

FAMILY AFFAIR Mistress whos bedded over 100 married men says cheating is in your genes

PIC PERFECT Macho Wills and dominant Kate - what their Xmas cards really say about them

Go here to read the rest:
Six surprising Christmas gifts to give your man a boost in the bedroom from a vegan cookbook to a - The Sun

A vector is a microscopic carrier of pieces of DNA. It is used to deliver healthy copies of genes to tissues and organs within patients or deliver the ability to correct the genetic errors. While the technology is moving rapidly, production of vectors is not.

NSW, and in particular the Westmead Precinct, is already at the forefront of international gene therapy research. The aim of this project is to speed up research and translate it into cures for serious genetic diseases affecting children.

The facility will produce vectors to treat illnesses impacting everything from those with life-threatening liver disease to children going blind. Currently the vectors need to imported and its extremely costly to get them to Australia.

Professor Ian Alexander, Head of the Gene Therapy Research Unit at Childrens Medical Research Institute, senior clinician at The Childrens Hospital at Westmead and Professor of Paediatric and Molecular Medicine at the University of Sydney, said the manufacturing facility would be a boost to translation of academic research in NSW.

We see it as the beginning of something much greater, Professor Alexander said.

It is about moving technology into the clinic, which, in future, will benefit many more patients by offering new and better treatment opportunities. This technology could translate into saving the lives of infants with life-threatening conditions.

Dr Leszek Lisowski heads the Translational Vectorology Group at CMRI and is Conjoint Senior Lecturer at the University of Sydney. His team will play a key role in the new facility, through training of staff and developing the manufacturing processes that will underpin operations. In addition, his team specialises in the development of novel vectors optimised for clinical applications targeting liver, eye and many other clinically important organs and tissues.

Dr Lisowski said that this new facility will allow Australian investigators to get around the "bottleneck" of getting vectors from overseas.

The biggest bottleneck that slows down translation of gene therapy tools to the patient is a global lack of vector manufacturing capacity, which significantly extends the timeline and increases the cost of translational studies," he said.

This facility will give Australian researchers prioritised and cost-effective access to clinical gene therapy reagents and will facilitate translation of a large number of exciting preclinical programs from bench to bedside.

The team is excited by this vital investment and looks forward to partnering with government and other funders to enable the facility to achieve its full potential.

The Westmead Precinct is one of the largest health, education, research and training precincts in Australia and a key provider of jobs for the greater Parramatta and western Sydney region. Spanning 75 hectares, the Precinct includes four hospitals, four world-leading medical research institutes, two multidisciplinary university campuses and the largest research-intensive pathology service in NSW.

The University of Sydney has long been a proud partner of the Precinct and is in negotiations about developing a second major campus in the area. By 2050, that campus will include 25,000 students; 1000 staff and researchers; generate $21.7 billion for the NSW economy and support up to 20,000 jobs.

University of Sydney Vice-Chancellor and Principal Dr Michael Spence said that as part of our collaborative work in building a western Sydney global centre of excellence, Precinct partners are growing Australias advanced manufacturing capability.

These developments will strengthen crucial collaborations in the Precinct from R&D and design to distribution in areas such as prevention and wellbeing, biomedical engineering, AI and personalised medicine, Dr Spence said.

Faculty of Medicine and Health Executive Dean Professor Robyn Ward said: This technology will scale up gene therapy using viral vectors from single-condition, life changing successes, for example in spinal muscle atrophy, to a national service.

We are so proud of this leadership at the Westmead Precinct and with our health partners. It is a whole-of-lifespan, true bench-to-clinic approach."

Read this article:
Westmead advanced manufacturing to transform lives - News - The University of Sydney

Pakistani and Chinese experts have done the successful clinical trial of the first traditional Chinese medicine (TCM) Yinhuang Qingfei Capsules in Pakistan as a revolutionary step in the countrys healthcare system.

He shared the details of clinical confirmatory trials that they were conducted by the Center for Bio equivalence Studies and Clinical Research (CBSCR), which works as a component of Dr. Panjwani Center for Molecular Medicine and Drug Research, University of Karachi to introduce the effective treatment strategies and drugs for patients with chronic bronchitis in Pakistan.

He mentioned that the clinical trial was carried out by using randomized, double-blind, double-simulation positive control study to assess the efficacy and effectiveness of Yinhuang Qingfei Capsules on patients with acute exacerbation of chronic bronchitis in Pakistan.

He informed that total of 212 patients (aged 18 to 65) with an acuteattackof chronic bronchitis were selected and diagnosed and evaluated according to the criteria of western medicine.

The press conference held at the International Center for Chemical and Biological Sciences (ICCBS), University of Karachi was attended by number of medical experts from Pakistan and China

Yinhuang Qingfei Capsules was a natural herbs preparation developed by Hunan Anbang Pharmaceutical for the treatment of an acuteattackof chronic bronchitis.

Chronic bronchitis is a common disease related to chronic inflammation, which is caused by a variety of pathogenic factors, such as air pollution, smoking, and pathogen infection.

Director of the ICCBS Prof. Dr. Muhammad Iqbal Choudhary said the trial of a traditional Chinese medicine for the first time in Pakistan is a historic step which will open new opportunities of cooperation in the field of medicine between the two countries.

He further said Because of its satisfactory clinical efficacy, as the main component of complementary and alternative drug therapy, herbal preparation of natural medicine has drawn more attention from all over the world, which has also played an important role in the prevention and treatment of chronic bronchitis.

Chairman of the Hunan Federation of Industry and Commerce Zhang Jian told the audience that the success of the clinical trial shows that Chinese patent medicine has officially entered Pakistan.

Chairman of Anbang Pharmaceutical Chen Feibao said the effectiveness of Yinhuang Qingfei capsule to treat Chronic Obstructive Pulmonary Disease is higher than its competitor western medicine but its price is only 5 percent of that which will reduce the financial burden on Pakistani patients.

Chinese experts present on the occasion said the traditional capsule was a natural herb preparation developed for the treatment of acuteattackof chronic bronchitis.

Support us by sharing this content 🙂

View original post here:
Experts done successful clinical trial of 1st Chinese medicine in Pakistan as alternative of antibiotics - Technology Times Pakistan

For her masters degree in biotechnology, Pallavi Venkatesh didnt just learn about the latest advances in medical science, she made some too.

Pallavi studied one of the most important tools in modern medicine, the Vaccinia virus, which was used as a vaccine to eradicate smallpox.

I found out that different strains of the virus preference different pathogen-sensing molecules found within immune cells, which is really exciting, she says.

Better understanding how different virus strains are detected by immune cells could help fine-tune its use as a tool against cancers and other viruses in the future.

Our finding was exciting as we found that more than one of these pathogen sensor molecules was involved and that different strains may activate different sensor molecules preferentially.

Pallavi says the coursework components of her Master of Biotechnology (Advanced) at The Australian National University (ANU) gave her the skills she needed to undertake this original research.

I studied genomic sciences, molecular biology and cell biology, which I really enjoyed, she says.

For the research component of her degree, she had the opportunity to be part of an innovative team at The John Curtin School of Medical Research (JCSMR).

I did my research under David Tscharke in the Immunology Department, she says.

Working with David was an amazing learning opportunity, he pushes you to be the best you can and provides incredible support.

I also received additional support from members of the lab which helped me through my research year.

Prior to arriving at ANU, Pallavi completed her undergraduate degree at Jyoti Nivas College in Bangalore.

She says that Canberra and living on campus at Toad Hall provided the ideal environment for a postgraduate scholar.

I highly recommend ANU as a place to study, she says. I made lots of new friends here, friends for life.

Inspired by her time at JCSMR, Pallavi is now planning to pursue a career in immunology.

Find out more about how a Master of Biotechnology at ANU can help launch your career in medical, biological or agricultural science.

See more here:
Graduating with a master's degree AND a medical discovery - Science at ANU

Dr. Karl Jacob Jr. and Karl Jacob III Early-Career Chair Eun Ji Chung. Photo courtesy of Viterbi Staff.

Eun Ji Chung, USC Viterbis Dr. Karl Jacob Jr. and Karl Jacob III Early-Career Chair and Assistant Professor of Biomedical Engineering, Chemical Engineering and Materials Science, has recently been honored by the Institute of Electrical and Electronics Engineers (IEEE) and the Biomedical Engineering Society (BMES) for her research in nanomedicine and bioengineering.

The IEEE has selected Chung as a NANOMED New Innovator, with the award to be presented at the IEEE International Conference on Nano/Molecular Medicine and Engineering in Gwangju, Korea on 21 24 November. The latest honor recognizes Chungs eminent research activities in the field of nanomedicine and molecular engineering as well as her continuous contribution to the IEEE-NANOMED community.

Meanwhile the BMES will honor Chung with the 2020 Rising Star Junior Faculty Award, to be presented at the BMES Cell and Molecular Bioengineering conference on January 2 6 in Puerto Rico. Chung will be recognized at the conference gala, and will be invited to present at the event. The BMES describes the Rising Star Award as a leading form of recognition of outstanding research in the field of cell and molecular bioengineering.

Chung and her research groupinvestigate molecular design, nanomedicine and tissue engineering to generate biomaterial strategies for clinical applications. A key focus of Chungs labs research involves the design and application of self-assembling, peptide nanoparticles for targeted cardiovascular and cancer treatments, as well as for the treatment of kidney disease.

A faculty member of theUSC Michelson Center for Convergent Bioscience, Chung received her B.A. in Molecular Biology with honors from Scripps College, Claremont, California, and her Ph.D. from the Interdisciplinary Biological Sciences Program and the Department of Biomedical Engineering from Northwestern University.

She was recently named 2019 Orange County Engineering Council Outstanding Young Engineer and a Journal of Materials Chemistry B Emerging Investigator for 2019.

Last year, Chung was awarded the NIH New Innovator Award to develop a new approach to a type of kidney disease, known as autosomal dominant polycystic kidney disease, the most commonly inherited kidney disorder.

Chung is a recipient of the SQI-Baxter Early Career Award, the American Heart Association Postdoctoral Fellowship, the Postdoctoral Research Grant from the Chicago Biomedical Consortium, and the K99/R00 Pathway to Independence Award from the NIH. She is a member of the Society for Biomaterials, the BMES, and the American Institute for Chemical Engineers.

Here is the original post:
Eun Ji Chung Named as IEEE New Innovator and BMES Rising Star - USC Viterbi School of Engineering